Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients

Quality of Life Research

Volumn 15, Issue 8, 2006, Pages 1383-1394

  Cole, Jason C ^a,b   Khanna, Dinesh ^c,d,e   Clements, Philip J ^f   Seibold, James R ^g   Tashkin, Donald P ^f   Paulus, Harold E ^f   Irwin, Michael R ^h   Motivala, Sarosh J ^h   Furst, Daniel E ^f  

^a THE MEASUREMENT GROUP   (United States)

^b QualityMetric   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Confirmatory factor analysis; HAQ DI; Latent analysis; Rheumatoid arthritis; Systemic sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; RELAXIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG ALVEOLITIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCLERODERMA; SCORING SYSTEM; SYSTEMIC SCLEROSIS; VALIDITY;

ACTIVITIES OF DAILY LIVING; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MULTICENTER STUDIES; PSYCHOMETRICS; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; SCLERODERMA, SYSTEMIC; SICKNESS IMPACT PROFILE; UNITED STATES;

EID: 33750553150     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-006-0018-8     Document Type: Article

References (55)

1. Medsger TA Jr. System sclerosis: Clinical aspects. In: Koopman W (ed.), Arthritis and Allied Conditions. Baltimore: Williams and Wilkins, 19971433-1464.
2. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-145.
3. Cole JC, Motivala SJ, Khanna D, Lee JY, Paulus HE, Irwin MR. Validation of a single-factor structure and the scoring protocol for the Health Assessment Questionnaire-Disability Index (HAQ-DI). Arthritis Care Res 2005; 53: 536-542.
4. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with system sclerosis and active alveolitis: Results from the Scleroderma Lung Study. Arthritis Rheum 2005; 52: 592-600.
5. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 832-840.
6. Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes MD, White B, et al. The disability index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in system sclerosis trial. Arthritis Rheum 2001; 44: 653-661.
7. Messick S. Validity of psychological assessment: Validation of inferences from persons' responses and performances as scientific inquiry into score meaning. Am Psychol 1995; 50: 741-749.
8. Haynes SN, Richard DCS, Kubany ES. Content validity in psychological assessment: A functional approach to concepts and methods. Psychol Assess 1995; 7: 238-247.
9. Vandenberg RJ, Lance CE. A review and synthesis of the measurement invariance literature: Suggestions, practices, and recommendations for organizational research. Organ Res Method 2000; 3: 4-70.
10. Meade AW, Lautenschlager GJ. A comparison of item response theory and confirmatory factor analytic methodologies for establishing measurement equivalence/invariance. Organ Res Method 2004; 7: 361-388.
11. Seibold JR, Clements PJ, Korn JH, Ellman M, Rothfield N, Wigley FM, et al. US phase III trial of relaxin in diffuse scleroderma [Abstract]. J Rheumatol 2001; 63: T-64.
12. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. J Rheumatol 1980; 23: 581-590.
13. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes MD, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43: 2445-2454.
14. Tashkin DP, Elashoff D, Clements PJ, Golding JM, Roth MD et al. Cyclophosphamide versus placebo in scleroderma lung disease. New Engl J Med (in press).
15. Khanna D, Ranganath VK, Fitzgerald J, Park GS, Altman RD, Elashoff D, et al. Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands but not with more rapid progression of damage. Arthritis Rheum 2005; 52: 2284-2292.
16. Wu H, Khanna D, Park GS, Gersuk V, Nepom GT, Wong WK, et al. Interaction between RANKL and HLA-DRB1 genotypes may contribute to younger age at onset of seropositive rheumatoid arthritis in an inception cohort. Arthritis Rheum 2004; 50: 3093-3103.
17. Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes MD, White B, et al. Correlates of the disability index of the Health Assessment Questionnaire: A measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999; 42: 2372-2380.
18. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Seibold JR. Responsiveness of the health related quality of life instruments (sf-36 and HAQ-DI) in a systemic sclerosis clinical trial [Abstract]. Arthritis Rheum 2003; 48: S398.
19. Kumar A, Malaviya AN, Pandhi A, Singh R. Validation of an Indian of the Health Assessment Questionnaire in patients with rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 1457-1459.
20. El Meidany YM, El Gaafary MM, Ahmed I. Cross-cultural adaptation and validation of an Arabic Health Assessment Questionnaire for use in rheumatoid patients. Joint Bone Spine 2003; 70: 195-202.
21. El Meidany YM, Youssef S, El Gaafary MM, Ahmed I. Evaluating changes in health status: sensitivity to change of the modified Arabic Health Assessment Questionnaire in patients with rheumatoid arthritis. Joint Bone Spine 2003; 70: 509-514.
22. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New Engl J Med 2000; 343: 1586-1593.
23. Lipsky PE, Heijde DMvan der, St. Clair EW, Smolen JS, Furst JS, Kalden JR, et al. 102-week clinical and radiologic results from the ATTRACT trial: A 2-year, randomized, controlled, phase 3 trial of infliximab in patients with active RA despite MTX. Arthritis Rheum 2000; 43: S269.
24. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patient taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
25. Wolfe F, Hawley DJ. The long term outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients. J Rheumatol 1998; 25: 2108-2117.
26. Wolfe F. The determination and measurement of functional disability in rheumatoid arthritis. Arthritis Res 2002; 4: S11-S15.
27. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patient with rheumatoid arthritis. Arthritis Rheum 2003; 48: 1530-1542.
28. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: Dimensions and practical applications. Health Qual Life Outcomes 2003; 1: 1-6.
29. Westhovens R, Cole JC, Li T, Martin M, MacLean R, Lin P et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicenter randomized clinical trial. Rheumatology (in press).
30. MacCallum RC, Browne MW, Sugawara HM. Power analysis and determination of sample size for covariance modeling. Psychol Method 1996; 1: 130-149.
31. Arbuckle JL. Amos. In. 6.0 ed. Chicago: Small Waters, 2005.
32. Cole JC, Motivala SJ, Dang J, Lucko A, Lang N, Levin MJ, et al. Structural validation of the Hamilton Depression Rating Scale. J Psychopathol Behav Assess 2004; 26: 241-254.
33. Cole JC, Rabin AS, Smith TL, Kaufman AS. Development and validation of a Rasch-derived CES-D short form. Psychol Assess 2004; 16: 360-372.
34. Nevitt J, Hancock GR. Improving the root mean square error of approximation for nonnormal conditions in structural equation modeling. J Exp Educ 2000; 68: 251-268.
35. Bollen K, Stine RA. Bootstrapping goodness-of-fit measures in structural equation models. Sociol Method Res 1992; 21: 205-229.
36. Finney SJ, DiStefano C. Nonnormal and categorical data in structural equation modeling. In: Hancock GR, Mueller RO (eds.), Structural Equation Modeling: A Second Course. Greenwich, CT:IAP, 2006269-314.
37. Nevitt J, Hancock GR. Evaluating small sample approaches for model test statistics in structural equation modeling. Multivar Behav Res 2004; 39: 439-478.
38. Schumacker RE, Lomax RG. A Beginner's Guide to Structural Equation Modeling. Mahwah, NJ: Lawrence Erlbaum, 1996.
39. Marsh HW, Hau K-T, Wen Z. In search of golden rules: Comment on hypothesis-testing approaches to setting cutoff values for fit indexes and dangers in overgeneralizing Hu and Bentler's (1999) findings. Struct Equation Model 2004; 11: 320-341.
40. Bentler PM, Bonett DG. Significance tests and goodness-of-fit in the analysis of covariance structures. Psychol Bull 1980; 88: 588-606.
41. Hu L-t, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equation Model 1999; 6: 1-55.
42. Cheung GW, Rensvold RB. Evaluating goodness-of-fit indexes for testing measurement invariance. Struct Equation Model 2002; 9: 223-255.
43. Arbuckle JL, Wothke W. Amos 4.0 User's Guide, 4.01 ed. Chicago: Small Waters, 1999.
44. Cohen J. Statistical Power Analysis for the Behavioral Sciences., 2nd ed., Hillsdale: Lawrence Erlbaum, 1988.
45. Palmer RF, Graham JW, Taylor B, Tatterson J. Construct validity in health behavior research: Interpreting latent variable models involving self-report and objective measures. J Behav Med 2002; 25: 525-550.
46. Anastasi A, Urbina S. Psychological Testing., 7th ed., Upper Saddle River, NJ: Prentice Hall, 1998.
47. Hershberger SL. The problem of equivalent structural models. In: Hancock GR, Mueller RO (eds.), Structural Equation Modeling: A Second Course. Greenwichm, CT:IAP, 200613-42.
48. Muthén BO, Muthén LK. Mplus 3.0 User's Guide. Los Angeles: Muthén and Muthén, 2004.
49. Schumacker RE, Lomax RG. A Beginner's Guide to Structural Equation Modeling., 2nd ed., Mahwah, NJ: Lawrence Erlbaum, 2004.
50. Comrey AL, Lee HB. A First Course in Factor Analysis., 2nd ed., Hillsdale, NJ: Lawrence Erlbaum, 1992.
51. Hu L-t, Bentler PM. Evaluating model fit. In: Hoyle RH (ed.), Structural Equation Modeling: Concepts, Issues, and Applications. Thousand Oaks, CA:Sage, 1995.
52. Marsh HW, Hau K-T, Grayson D. Goodness of fit in structural equation models. In: Maydeu-Olivares A, McArdle JJ (eds.), Contemporary Psychometrics. Mahwah, NJ:Lawrence Erlbaum, 2005275-340.
53. Byrne BM. Structural Equation Modeling with AMOS: Basic Concepts, Applications, and Programming. Mahwah, NJ: Lawrence Erlbaum, 2001.
54. Bentler PM, Chou C. Practical issues in structural modeling. Sociol Method Res 1987; 16: 78-117.
55. Hancock GR. Power analysis in covariance structure modeling. In: Hancock GR, Mueller RO (eds.), Structural Equation Modeling: A Second Course. Greenwich, CT:IAP, 200669-118.